TCG Crossover Management, LLC

TCG Crossover Management, LLC reported 57 holdings worth US$3.54B as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

TCG Crossover Management, LLC reported 57 holdings worth US$3.54B as of Sep 30, 2026. Largest: Abivax SA, CG Oncology, Inc. and Amylyx Pharmaceuticals, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
57
Value as reported
US$3.54B

The filing in full

CompanySharesValue as reported% of portfolio
Abivax SA3.66MUS$363M10.2%
CG Oncology, Inc.3.67MUS$260M7.4%
Amylyx Pharmaceuticals, Inc.6.24MUS$182M5.1%
Spyre Therapeutics, Inc.1.9MUS$169M4.8%
Tango Therapeutics, Inc.6.77MUS$169M4.8%
Zai Lab Ltd.6.23MUS$164M4.6%
Immunovant, Inc.4.46MUS$151M4.3%
Dianthus Therapeutics, Inc.1.68MUS$148M4.2%
Kodiak Sciences Inc1.45MUS$137M3.9%
Vor Biopharma Inc.5.67MUS$108M3.1%
First Tracks Biotherapeutics, Inc.2.9MUS$103M2.9%
Mirum Pharmaceuticals, Inc.1.12MUS$95.6M2.7%
BioCryst Pharmaceuticals, Inc.11MUS$91.8M2.6%
Disc Medicine, Inc.1.34MUS$87.8M2.5%
ADARx Pharmaceuticals, Inc.4.12MUS$82.1M2.3%
Cogent Biosciences, Inc.2.5MUS$80.1M2.3%
Tyra Biosciences, Inc.3.48MUS$76M2.1%
Dyne Therapeutics, Inc.4.62MUS$74.3M2.1%
Relay Therapeutics, Inc.3.78MUS$68.3M1.9%
Aura Biosciences, Inc.10.2MUS$63.8M1.8%
Savara, Inc.12.4MUS$63.8M1.8%
Xencor, Inc.2.06MUS$51.3M1.4%
Avalo Therapeutics, Inc.3.02MUS$46.3M1.3%
Monte Rosa Therapeutics, Inc.3.78MUS$45.1M1.3%
MBX Biosciences, Inc.650KUS$38.1M1.1%
Janux Therapeutics, Inc.1.79MUS$30.9M0.87%
Tarsus Pharmaceuticals, Inc.388KUS$30.5M0.86%
Century Therapeutics, Inc.17.8MUS$30.4M0.86%
Obsidian Therapeutics, Inc.2.2MUS$30.2M0.85%
LB Pharmaceuticals Inc765KUS$29.4M0.83%
Editas Medicine, Inc.11.1MUS$28.6M0.81%
Tectonic Therapeutic, Inc.1.2MUS$28.1M0.79%
Perspective Therapeutics, Inc.7.92MUS$21.8M0.61%
AgomAb Therapeutics NV1.82MUS$20.2M0.57%
Silence Therapeutics PLC1.82MUS$19.9M0.56%
Alector, Inc.10MUS$18.5M0.52%
Biohaven Ltd.1.26MUS$16.9M0.48%
Monopar Therapeutics Inc.202KUS$16.1M0.46%
Entrada Therapeutics, Inc.1.06MUS$6.73M0.19%
Cullinan Therapeutics, Inc.407KUS$6.24M0.18%
Agenus Inc.604KUS$6M0.17%
Ocular Therapeutix, Inc.720KUS$5.52M0.16%
Arvinas, Inc.707KUS$5.47M0.15%
Korro Bio, Inc.416KUS$4.13M0.12%
Research Alliance Corporation IV300KUS$3.6M0.10%
ALX Oncology Holdings Inc.2.47MUS$3.43M0.10%
Aktis Oncology, Inc.133KUS$2.6M0.07%
JATT II Acquisition Corp200KUS$2.25M0.06%
LeonaBio, Inc.464KUS$1.66M0.05%
JATT III Acquisition Corp100KUS$1.1M0.03%
Context Therapeutics Inc.2.68MUS$806K0.02%
Eikon Therapeutics, Inc.37,902US$305K<0.01%
Research Alliance Corporation III0US$00.00%
Revolution Medicines, Inc.0US$00.00%
Surrozen, Inc.0US$00.00%
Altimmune, Inc.0US$00.00%
Forte Biosciences, Inc.0US$00.00%

Source

Download original · View original at SEC

Related